How to Get Tresiba in District of Columbia

What Is Tresiba and Why Do Patients in DC Seek It

Tresiba is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, making it the longest-acting commercially available insulin in the United States. Novo Nordisk received FDA approval in September 2015 for both type 1 and type 2 diabetes in adults, and the FDA later expanded the label to include pediatric patients aged 1 year and older [1].

The DEVOTE cardiovascular outcomes trial (N=7,637) compared insulin degludec to insulin glargine U-100 over a median follow-up of 2 years. Degludec met non-inferiority for major adverse cardiovascular events (MACE) and produced a 40% relative risk reduction in severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) [2]. That hypoglycemia advantage is the primary clinical reason DC providers switch patients to Tresiba from older basal insulins.

DC patients also seek Tresiba because its flexible dosing window, up to 8 hours between injections on any given day, accommodates shift workers and patients with irregular schedules, a practical benefit for many residents of a high-density urban area [1].

Telehealth Prescribing of Tresiba in District of Columbia

DC permits telehealth prescribing of Tresiba for both new and established patients. DC telehealth providers may write a valid Schedule III insulin prescription after a synchronous audio-visual visit that meets the DC Health Telemedicine Standards, meaning the provider must conduct a clinical evaluation sufficient to establish a diagnosis before prescribing [3].

This matters practically. A DC-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via video, review uploaded glucose logs or continuous glucose monitor (CGM) data, and send a Tresiba prescription electronically to any DC-licensed pharmacy the same day. The DC Board of Medicine and DC Board of Nursing do not require an in-person visit before an insulin prescription can be written [3].

Patients should verify that a telehealth platform has an active DC prescriber on staff, not merely a prescriber licensed in a neighboring jurisdiction. Virginia and Maryland licenses do not permit prescribing to DC residents without separate DC licensure.

The HealthRX clinical team uses a three-step telehealth intake for Tresiba candidates in DC:

1. Synchronous video visit (15 to 30 minutes) covering diabetes history, current insulin regimen, hypoglycemia frequency, and CGM or glucometer data.
2. Same-day electronic prescription sent to the patient's preferred DC pharmacy or a mail-order pharmacy licensed in DC.
3. Follow-up message or call at 72 hours to confirm dose receipt and answer titration questions.

Who Can Prescribe Tresiba in District of Columbia

Four practitioner types hold legal prescriptive authority for Tresiba in DC. MDs and DOs licensed by the DC Board of Medicine may prescribe without restriction [4]. Nurse practitioners licensed by the DC Board of Nursing hold full independent prescriptive authority in DC, meaning they do not require physician supervision or a collaborative practice agreement to write insulin prescriptions [5]. Physician assistants licensed by the DC Board of Medicine may prescribe Tresiba under a supervision agreement with a DC-licensed physician [4].

Endocrinologists, primary care physicians, internal medicine doctors, and family medicine NPs all routinely prescribe Tresiba in DC. Patients without an existing endocrinologist can receive a first prescription from a telehealth general practitioner, then transition to specialist care if glycemic targets are not met within 90 days.

The American Diabetes Association's Standards of Care in Diabetes 2024 state: "Insulin therapy should be initiated in patients with type 1 diabetes at diagnosis and should be intensified whenever HbA1c or glucose targets are not met" [6]. Tresiba fits the basal insulin slot in any of the ADA's recommended multi-dose insulin regimens.

Lab Work Required Before Starting Tresiba in DC

No single blood test is legally required before a prescriber may dispense Tresiba, but responsible clinical practice and most telehealth platform protocols require a defined baseline panel. The following labs are standard before initiating or switching to insulin degludec.

HbA1c. An HbA1c within the prior 3 months establishes baseline glycemic control and determines starting dose direction. The ADA recommends an HbA1c target of <7.0% for most non-pregnant adults with diabetes [6]. Patients with HbA1c above 10% typically require a higher starting dose of Tresiba or a concurrent rapid-acting insulin.

Fasting glucose. A single fasting plasma glucose on the day of or prior to the visit quantifies current control and helps calibrate the initial Tresiba dose.

Basic metabolic panel (BMP). Renal function (creatinine, eGFR) and potassium levels are checked because insulin drives potassium intracellularly; hypokalemia worsens with insulin initiation [7]. Dose adjustments may be needed in patients with an eGFR <30 mL/min/1.73 m².

Thyroid function (TSH). Recommended at baseline for type 1 diabetes patients per ADA 2024 guidelines, given the high prevalence of autoimmune thyroid disease in type 1 [6].

C-peptide (optional but useful). In ambiguous cases where type 1 vs. type 2 classification is uncertain, a fasting C-peptide below 0.6 ng/mL supports a type 1 diagnosis and influences whether Tresiba will be the sole basal insulin or part of a basal-bolus regimen [8].

Patients can order these labs at any DC LabCorp or Quest Diagnostics draw site, or through a telehealth provider's standing order, and upload results to the telehealth platform before the prescribing visit.

Tresiba Dosing Basics Relevant to the DC Prescription Process

Understanding dosing helps DC patients ask the right questions during their telehealth visit and supports accurate prescription writing. The FDA-approved starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily [1]. For patients switching from another basal insulin, degludec is initiated unit-for-unit for most patients on glargine U-100 or detemir, though patients switching from glargine U-300 (Toujeo) may require a 20% dose reduction [1].

Titration follows a treat-to-target protocol. The SWITCH 2 trial (N=721) demonstrated that titrating degludec to a fasting glucose target of 71 to 90 mg/dL reduced overall symptomatic hypoglycemia by 30% compared to glargine U-100 under the same titration algorithm [9]. DC telehealth providers typically instruct patients to increase the Tresiba dose by 2 units every 3 days until fasting glucose consistently falls below 100 mg/dL, then hold.

The Tresiba FlexTouch pen delivers doses from 1 to 80 units per injection, which accommodates most adult patients. Patients requiring more than 80 units per injection need two injections at the same time each day [1].

Prior Authorization for Tresiba Under DC Medicaid and Commercial Insurance

DC Medicaid (DC Healthy Families, Alliance, and the Alliance for individuals not eligible for Medicaid) covers Tresiba for both type 1 and type 2 diabetes with prior authorization. The prior authorization (PA) process typically requires the following documentation [10]:

• Confirmed diagnosis of type 1 or type 2 diabetes with ICD-10 code (E10.x for type 1, E11.x for type 2).
• Current HbA1c result (within 90 days).
• Documented failure of or clinical contraindication to formulary-preferred basal insulins (usually glargine U-100 or NPH).
• Prescriber attestation that the patient has experienced recurrent hypoglycemia on the preferred agent, or that Tresiba is indicated for its flexible dosing.
• For type 1 patients, documentation of concurrent rapid-acting insulin use.

Most DC commercial plans, including CareFirst BlueCross BlueShield (the dominant DC insurer), also require step therapy through glargine before approving Tresiba. Telehealth providers experienced in DC PA submissions typically turnaround approval within 3 to 5 business days when documentation is complete.

The DC Department of Health Care Finance publishes preferred drug list updates quarterly; patients and prescribers should verify current Tresiba tier placement before submitting a PA to avoid formulary mismatches [10].

Transferring an Existing Tresiba Prescription to DC

Patients relocating to DC, or students arriving from other states, can transfer a Tresiba prescription to any DC-licensed pharmacy. DC law does not restrict insulin prescription transfers from out-of-state pharmacies to DC pharmacies, provided the original prescription was written by a licensed prescriber in the originating state and has remaining refills [4].

The receiving DC pharmacy will call the originating pharmacy to verify the prescription. Transfers of controlled substances differ, but insulin is not a controlled substance in DC or federally, so no DEA paperwork is required.

Patients who have an out-of-state prescription with no remaining refills need a new prescription from a DC-licensed provider. A telehealth visit is the fastest option; most platforms in DC can issue a new prescription within 24 hours of a video visit if labs are on file.

Out-of-state prescriptions written by VA or military providers may require additional verification steps at DC retail pharmacies. Patients using military pharmacies (e.g., Walter Reed at the DC border) should confirm whether their current prescriber holds a DC license or whether a separate DC prescription is needed for civilian pharmacies.

503A Compounding Pharmacies and Insulin Degludec in DC

503A pharmacies are patient-specific compounding pharmacies licensed under state law, as distinct from 503B outsourcing facilities regulated as manufacturers by the FDA. DC-licensed 503A pharmacies may compound insulin degludec preparations for individual patients when a valid prescription is presented and a documented clinical need for the compounded formulation exists [11].

Compounded insulin degludec is not interchangeable with FDA-approved Tresiba. The FDA notes that compounded drugs lack the safety and efficacy demonstration of approved products and should be used only when an FDA-approved alternative is not suitable for the individual patient [11]. Common reasons a provider might direct a DC patient to a 503A pharmacy include allergy to an excipient in the commercial product or a need for a concentration not commercially available.

Patients should ask any 503A pharmacy for proof of DC licensure and USP 797 compliance documentation before accepting a compounded insulin preparation. DC's Board of Pharmacy oversees 503A facilities in the District [12].

Retail and Mail-Order Pharmacy Options for Tresiba in DC

Tresiba is stocked at most major retail pharmacy chains operating in DC, including CVS, Walgreens, and Giant Food pharmacy locations. The list price for Tresiba FlexTouch (5 pens, 3 mL each, 100 units/mL) without insurance is approximately $530 per box, though this varies by pharmacy [13].

Novo Nordisk's My$99Insulin patient assistance program caps out-of-pocket cost at $99 per 30-day supply for eligible uninsured patients. Patients with commercial insurance who meet income thresholds may qualify for the Novo Nordisk Patient Assistance Program, which can reduce cost to $0 per month [13].

Mail-order pharmacies licensed in DC, including Novo Nordisk's authorized specialty pharmacy network, can ship Tresiba directly to DC addresses. Cold-chain shipping (2 to 8 degrees Celsius) is required for unopened Tresiba pens. An open Tresiba pen stored at room temperature below 86 degrees Fahrenheit (30 degrees Celsius) is stable for 56 days [1].

The FDA's MedWatch program allows DC patients to report insulin quality concerns, including pen delivery failures, via the FDA Safety Reporting Portal [14].

What to Expect: Timeline From Telehealth Visit to First Injection in DC

The fastest path for a DC patient to receive Tresiba runs roughly as follows:

Day 0. Patient uploads existing labs (HbA1c within 90 days, fasting glucose, BMP) to a telehealth platform and books a same-day or next-day video visit.

Day 1. Video visit completed. Prescriber sends electronic prescription to the patient's chosen DC retail pharmacy.

Day 1 to 2. Patient picks up Tresiba at retail pharmacy after insurance verification or copay arrangement. Without insurance, a GoodRx coupon at major DC pharmacies typically reduces the cost by 15 to 30% from list price.

Day 2 to 7. If the patient opts for mail-order, cold-chain shipping from a DC-licensed mail-order pharmacy typically arrives within 2 to 5 business days of prescription receipt.

The ADA and the Endocrine Society both recommend that patients initiating basal insulin receive structured education on injection technique, hypoglycemia recognition and treatment, and self-monitoring of blood glucose [6][15]. DC telehealth platforms should provide at minimum a written instruction sheet and a follow-up contact within 72 hours of the first injection.

Hypoglycemia Risk and Safety Considerations Specific to Tresiba

Degludec's flat pharmacokinetic profile reduces day-to-day variability in insulin absorption compared to glargine U-100, which is the mechanistic basis for its lower hypoglycemia rate. In DEVOTE, the annualized rate of severe hypoglycemia was 0.20 episodes per patient-year with degludec vs. 0.35 with glargine U-100 (P<0.001) [2].

DC patients should be counseled to carry 15 to 20 grams of fast-acting carbohydrate (e.g., glucose tablets or 4 ounces of juice) at all times during dose titration. The ADA defines severe hypoglycemia as an event requiring third-party assistance [6]. Patients who experience two or more mild hypoglycemic episodes per week should contact their prescribing provider before the next scheduled follow-up.

Drug interactions that increase hypoglycemia risk with degludec include alcohol, beta-blockers (which mask tachycardia symptoms), ACE inhibitors, and concurrent sulfonylurea or GLP-1 receptor agonist use [1]. Patients combining Tresiba with a GLP-1 agonist such as semaglutide (Ozempic or Wegovy) should expect that the GLP-1's glucose-lowering effect may require a Tresiba dose reduction to avoid hypoglycemia [1][16].

The FDA label for Tresiba includes a Black Box Warning for hypoglycemia, noting it is the most common adverse reaction and may be life-threatening [1].